Artificial Intelligence has created a new drug

Now the pharmaceutical industry unloads everything on AI: it is they who create the most suitable drugs for Man | First tests on humans, incredible results

Insilico Medicine is the first pharmaceutical company to bring an AI-developed drug into phase II

iPaddisti.it – 1 luglio 2023

Even pharmaceutical companies surrender to artificial intelligence: the first drug created by AI is being tested. Its name is NS018_055, and it was designed to treat idiopathic pulmonary fibrosis. Access to phase II trials on human patients is a stumbling block for the 90% of drugs, but the trend is well defined: in the future, more and more pharmaceutical companies will make use of the help of artificial intelligence to develop their own drugs.

Artificial intelligence is revolutionizing the world we live in, offering new opportunities and innovative solutions in various sectors. From robotics to medicine, through industry and education, the applications of AI are virtually endless.

However, along with these benefits, AI also brings with it a number of risks and challenges, including the need to ensure data security and privacy, the management of social inequalities and the regulation of its use. The challenges facing society are many when it comes to AI. In the field of pharmaceutical research and development, AI is playing an increasingly important role. An emblematic example is represented by NS018_055, the first drug developed with the help of artificial intelligence by Insilico Medicines, a biotech startup.

The first drug created by AI to be tested: the future of medicine is marked

This drug, designed to treat idiopathic pulmonary fibrosis, recently passed Phase I clinical trials and is now entering phase II, which involves testing on a larger number of patients. Insilico Medicine's success is just the tip of the iceberg of a larger trend he sees more and more startups and pharmaceutical companies use AI to accelerate the development of new medicines. However, despite the enormous potential of this technology, the path to new drug approval is long and complex, and most drug candidates does not pass stage II of clinical trials.

Despite these difficulties, the use of AI in the pharmaceutical field is set to grow. With its ability to analyze massive amounts of data and identify complex patterns, AI can help researchers discover new therapeutic targets, to design pharmacologically active molecules it's at predict side effects of a drug. In this way, AI can help make the drug development process faster, cheaper and more effective, with enormous benefits for patients and the entire healthcare system.

Related news: Perché l’intelligenza artificiale riesce a trovare nuovi farmaci così rapidamente

AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor

Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform

AI won't replace science whistleblowers, but it can help them — here's how